TY - JOUR T1 - Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer JF - Journal of Investigative Medicine JO - J Investig Med SP - 1329 LP - 1341 DO - 10.1136/jim-2021-002298 VL - 70 IS - 6 AU - Sayed Reshad Ghafouri AU - Suvarna Guvvala AU - Catherine Jones AU - Alexander Philipovskiy Y1 - 2022/08/01 UR - http://hw-f5-jim.highwire.org/content/70/6/1329.abstract N2 - Breast cancer (BC) is the most common cancer affecting women worldwide. In 2021, the estimated number of new breast cancer cases was 281 550 and about 43 500 women died from metastatic breast cancer (mBC). For women aged 20–59 years, mBC remains the leading cause of cancer death and is, therefore, an important public health concern. Only 5% of women initially present with metastatic disease. Approximately 20% of patients presenting with local or locoregional disease progress to mBC despite adjuvant therapy. Inspite of all the medicosurgical advancements, the overall prognosis for patients diagnosed with mBC remains poor, with median overall survival of approximately 31 months, although this varies based on tumor biology. In recent years, there has been significant progress in developing immunotargeted therapies such as antihuman epidermal growth factor receptor 2 (anti-HER2) or check point inhibitors that confirmed to have dramatically improve the prognosis of mBC, a historically unfavorable disease subset. Even with the major progress that has been made in understanding the biology of BC, challenges such as resistance frequency to therapies, unknown efficacy, concerns for safety of drug combination and toxicities still remain high. Therefore, a new targeted and more selective treatment approaches are the need of the hour. In this review, we aim to outline the most recently approved medications in treatment of Her2-positive and triple-negative breast cancers. ER -